BR1100323A - Composto, uso de um composto, composição farmacêutica e processo para preparar um composto - Google Patents

Composto, uso de um composto, composição farmacêutica e processo para preparar um composto

Info

Publication number
BR1100323A
BR1100323A BR1100323-5A BR1100323A BR1100323A BR 1100323 A BR1100323 A BR 1100323A BR 1100323 A BR1100323 A BR 1100323A BR 1100323 A BR1100323 A BR 1100323A
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BR1100323-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Alfredo Cugola
Giovanni Gaviraghi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to BR1100323-5A priority Critical patent/BR1100323A/pt
Publication of BR1100323A publication Critical patent/BR1100323A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
BR1100323-5A 1992-04-16 1997-04-22 Composto, uso de um composto, composição farmacêutica e processo para preparar um composto BR1100323A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR1100323-5A BR1100323A (pt) 1992-04-16 1997-04-22 Composto, uso de um composto, composição farmacêutica e processo para preparar um composto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds
BR1100323-5A BR1100323A (pt) 1992-04-16 1997-04-22 Composto, uso de um composto, composição farmacêutica e processo para preparar um composto

Publications (1)

Publication Number Publication Date
BR1100323A true BR1100323A (pt) 2000-06-27

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR1100323-5A BR1100323A (pt) 1992-04-16 1997-04-22 Composto, uso de um composto, composição farmacêutica e processo para preparar um composto

Country Status (41)

Country Link
US (4) US5374649A (enExample)
EP (1) EP0568136A1 (enExample)
JP (2) JPH0649027A (enExample)
KR (1) KR100264114B1 (enExample)
CN (1) CN1042331C (enExample)
AP (1) AP480A (enExample)
AT (1) AT403917B (enExample)
AU (1) AU666927B2 (enExample)
BE (1) BE1006343A5 (enExample)
BG (1) BG62136B1 (enExample)
BR (1) BR1100323A (enExample)
CA (3) CA2094073A1 (enExample)
CH (1) CH685630A5 (enExample)
CY (1) CY2038B1 (enExample)
CZ (1) CZ285799B6 (enExample)
DK (1) DK169890B1 (enExample)
ES (1) ES2105924B1 (enExample)
FI (1) FI106198B (enExample)
FR (1) FR2690919B1 (enExample)
GB (2) GB9208492D0 (enExample)
GE (1) GEP19991704B (enExample)
GR (1) GR1001619B (enExample)
HK (1) HK95797A (enExample)
HU (2) HU217964B (enExample)
IL (1) IL105412A (enExample)
IS (1) IS3994A (enExample)
IT (1) IT1265325B1 (enExample)
LU (1) LU88248A1 (enExample)
MX (1) MX9302195A (enExample)
MY (1) MY112232A (enExample)
NO (1) NO301879B1 (enExample)
NZ (1) NZ247413A (enExample)
OA (1) OA10103A (enExample)
PL (1) PL176451B1 (enExample)
RO (1) RO113242B1 (enExample)
RU (1) RU2129544C1 (enExample)
SE (1) SE504336C2 (enExample)
SK (1) SK281941B6 (enExample)
TW (1) TW224457B (enExample)
WO (1) WO1993021153A1 (enExample)
ZA (1) ZA932642B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
CA2161768C (en) * 1993-05-27 1998-08-18 Francesco G. Salituro 3-(indol-3-yl) propenoic acid derivatives and as nmda antagonists
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (enExample) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
WO1998014427A1 (en) * 1996-09-30 1998-04-09 Hoechst Marion Roussel, Inc. Nmda (n-methyl-d-aspartate) antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
KR100440553B1 (ko) * 1998-03-26 2004-07-15 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
IL154049A0 (en) * 2000-07-31 2003-07-31 Dainippon Pharmaceutical Co Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
MXPA04005427A (es) * 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
MXPA05012895A (es) * 2003-06-05 2006-02-22 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa.
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
WO2005066135A2 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
RU2281755C2 (ru) * 2004-04-19 2006-08-20 Пятигорская государственная фармацевтическая академия Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для ректального применения
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
MX2008000250A (es) 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
RU2430913C2 (ru) 2006-01-06 2011-10-10 Сепракор Инк. Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
EP1978961B1 (en) * 2006-01-06 2016-03-16 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
CN101421228B (zh) 2006-03-31 2014-05-21 塞普拉柯公司 手性酰胺和胺的制备
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
EP2074092A2 (en) 2007-01-18 2009-07-01 Sepracor Inc. Inhibitors of d-amino acid oxidase
EP2617704B1 (en) 2007-05-31 2017-06-28 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CA2755118A1 (en) * 2009-03-10 2010-09-16 Santen Pharmaceutical Co., Ltd. Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
ES2911879T3 (es) 2014-04-30 2022-05-23 Tseng Yufeng Jane Uso de compuestos conocidos como inhibidores de la D-aminoácido oxidasa
NZ779170A (en) 2016-09-14 2025-08-29 Univ Nat Taiwan Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
KR102609676B1 (ko) 2017-06-12 2023-12-05 글리테크 엘엘씨. Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) * 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
KR0178469B1 (ko) * 1990-07-16 1999-03-20 메이나드 알. 존슨 흥분성 아미노산 길항제
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Also Published As

Publication number Publication date
BG62136B1 (bg) 1999-03-31
ES2105924A1 (es) 1997-10-16
NO943913D0 (no) 1994-10-14
IL105412A (en) 1998-02-22
ZA932642B (en) 1994-01-10
SE504336C2 (sv) 1997-01-13
IS3994A (is) 1993-10-17
US5374648A (en) 1994-12-20
TW224457B (enExample) 1994-06-01
RU94045915A (ru) 1996-09-10
DK169890B1 (da) 1995-03-27
DK43193D0 (da) 1993-04-15
ATA75293A (de) 1997-11-15
US5510367A (en) 1996-04-23
EP0568136A1 (en) 1993-11-03
GB2266091B (en) 1995-08-09
MX9302195A (es) 1994-03-31
CA2094073A1 (en) 1993-10-17
ITRM930236A1 (it) 1994-10-15
NO943913L (no) 1994-12-14
CA2094075A1 (en) 1993-10-17
CH685630A5 (fr) 1995-08-31
SE9301241L (sv) 1993-10-17
IL105412A0 (en) 1993-08-18
CZ285799B6 (cs) 1999-11-17
FR2690919A1 (fr) 1993-11-12
NZ247413A (en) 1995-12-21
IT1265325B1 (it) 1996-10-31
WO1993021153A1 (en) 1993-10-28
MY112232A (en) 2001-05-31
HUT70526A (en) 1995-10-30
FI944800L (fi) 1994-10-12
OA10103A (en) 1996-12-18
BE1006343A5 (fr) 1994-07-26
CY2038B1 (en) 1998-04-30
KR100264114B1 (ko) 2000-11-01
FR2690919B1 (fr) 1995-05-05
SE9301241D0 (sv) 1993-04-15
DK43193A (da) 1993-10-17
CN1085212A (zh) 1994-04-13
CA2094076A1 (en) 1993-10-17
NO301879B1 (no) 1997-12-22
ES2105924B1 (es) 1998-07-01
GEP19991704B (en) 1999-08-05
BG99111A (bg) 1995-05-31
AU3692393A (en) 1993-10-21
ITRM930236A0 (it) 1993-04-15
SK124194A3 (en) 1995-05-10
GR1001619B (el) 1994-07-29
US5374649A (en) 1994-12-20
LU88248A1 (fr) 1994-03-01
JPH07505407A (ja) 1995-06-15
FI106198B (fi) 2000-12-15
GB2266091A (en) 1993-10-20
RU2129544C1 (ru) 1999-04-27
SK281941B6 (sk) 2001-09-11
HU211826A9 (en) 1995-12-28
HU217964B (hu) 2000-05-28
HU9402975D0 (en) 1995-02-28
AU666927B2 (en) 1996-02-29
HK95797A (en) 1997-08-08
RO113242B1 (ro) 1998-05-29
GB9307808D0 (en) 1993-06-02
PL176451B1 (pl) 1999-05-31
JPH0649027A (ja) 1994-02-22
AP480A (en) 1996-03-22
CN1042331C (zh) 1999-03-03
GB9208492D0 (en) 1992-06-03
AP9300524A0 (en) 1993-04-30
AT403917B (de) 1998-06-25
CZ254394A3 (en) 1995-07-12
FI944800A0 (fi) 1994-10-12
US5373018A (en) 1994-12-13

Similar Documents

Publication Publication Date Title
BR1100323A (pt) Composto, uso de um composto, composição farmacêutica e processo para preparar um composto
BR9501770A (pt) Uso de um composto,composto,formulação farmacêutica e processo para preparar um composto
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
BR1100240A (pt) Composto; processo para a preparação de um composto; composição farmacêutica; e uso de um composto
BR9404809A (pt) Composto, uso, formulação farmacêutica e processo para preparar um composto
BR9505107A (pt) Composto composiçao farmacêutica processo para a preparaçao de um composto e seu uso
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9605354A (pt) Composto composição farmacêutica processo para a produção do composto e uso
BR1100979A (pt) Derivado de carboidrato, processo para preparar um derivado de carboidrato, composição farmacêutica de carboidrato e uso de derivado de carboidrato
BR9004852A (pt) Composto,processo para sua preparacao,sua aplicacao e composicao farmaceutica
BR9103036A (pt) Composto,formulacao farmaceutica e processo para a preparacao do composto
BR9301342A (pt) Composto,formulacao e composicao farmaceutica,processo para preparar um composto
BR9711340A (pt) Composto composi-Æo farmac-utica e processo para preparar um composto
BR9305161A (pt) Composto, composição farmacêutica e processo para a preparação do composto
BR9600339A (pt) Compostos composições farmacêuticas processo para a preparação de um composto e uso dos mesmos
BR9607264A (pt) Composto derivado do isotiuréia composição farmacêutica uso de tal composto e processo para a preparação dos mesmos
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto
BR9202446A (pt) Composicao de dentifricio,dentifricio e processo para a preparacao de um dentifricio
BR9406924A (pt) Composto processo para preparar o mesmo formulaçao farmaceutica e uso de um composto
BR9301273A (pt) Composto,formulacao farmaceutica,processo para preparar um composto e composto obtido
BR9606596A (pt) Composto processo para preparar um composto composição cosmética ou farmacéutica e uso de um composto
BR9106744A (pt) Processo para induzir diferenciacao celular,preparacao farmaceutica,composicao e uso de um composto

Legal Events

Date Code Title Description
AN Processing applications according to articles 230 and 231 of law 9279/96: notification of filing an application
HHFK Processing applications according to articles 230 and 231 of law 9.279/96: republication
FGAN Processing applications according to articles 230 and 231 of law 9.279/96: granting
NB Patent issued - articles 230 and 231 of law 9279/96